|
業務類別
|
Biotechnology |
|
業務概覽
|
Impact BioMedical Inc focuses on the advancement of drug discovery and prevention, inhibition, and treatment of neurological, oncological, and immune-related diseases. The company is also developing open-air defense initiatives, which curbtransmission of air-borne infectious diseases, such as tuberculosis and influenza. Its technologies inlcude Linebacker, Laetose, 3F, and Equivir. |
| 公司地址
| 1400 Broadfield Boulevard, Suite 130, Houston, TX, USA, 77084 |
| 電話號碼
| +1 281 415-6576 |
| 傳真號碼
| -- |
| 公司網頁
| https://www.impactbiomedinc.com |
| 員工數量
| 2 |
| Mr. Mark Suseck |
Chief Operating Officer |
美元 126.69K |
11/03/2026 |
| Mr. Todd D. Macko |
Chief Financial Officer, Principal Accounting Officer, Secretary and Treasurer |
-- |
11/03/2026 |
| Mr. Frank D. Heuszel |
Chief Executive Officer and Chairman of the Board |
美元 43.71K |
11/03/2026 |
|
|
| Mr. Heng Fai Ambrose Chan |
Director |
11/03/2026 |
| Mr. David Keene |
Independent Director |
11/03/2026 |
| Mr. Christian Zimmerman |
Independent Director |
11/03/2026 |
| Mr. Castel Hibbert |
Independent Director |
11/03/2026 |
| Dr. Elise Brownell, PhD |
Independent Director |
11/03/2026 |
| Ms. Melissa Sims |
Independent Director |
11/03/2026 |
| Mr. Frank D. Heuszel |
Chief Executive Officer and Chairman of the Board |
11/03/2026 |
| Mr. Jason Grady |
Director |
11/03/2026 |
|
|
|
|
